Opinion|Videos|July 15, 2024
Similarities and Differences Among PSMA-PET Tracers
Author(s)Tony Abraham, DO, MPA
A nuclear radiologist provides an overview of the gallium- and fluorine-based PSMA-PET tracer options, highlighting factors that influence tracer selection.
Advertisement
Episodes in this series
Video content above is prompted by the following questions:
- There are currently gallium- and fluorine-based PSMA-PET tracer options that are FDA approved. Can you review some of similarities and differences between the gallium and fluorine imaging tracer options identified above in terms of image quality and resolution? And accuracy and false positives?
- Gallium and fluorine tracers also have different half-lives. What does this mean in real-world practice in terms of patient scheduling and preparing for imaging? Can you provide any real-world examples of when one tracer may be preferential over another?
- There are two available F18 tracers available: 18F-Piflufolastat and 18F-Flotufolastat. What are some of the key differences between these? Can you share any examples of differences you’ve seen between these two tracers when used in real-world practice?
Advertisement
Related to this article
Pasritamig is being evaluated with or without JNJ-9401 in the ongoing phase 3 KLK2-comPAS trial.
These FAQs outline key recommendations from ASTRO's updated guideline on shorter-course radiation therapy for localized prostate cancer.
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
Alicia Morgans, MD, discusses ARACOG findings on cognitive outcomes with darolutamide vs enzalutamide and the influence of genetic dementia risk.
Aaron Berger, MD, discusses patient selection for ARPI treatment holidays, monitoring during interruptions, and the role of testosterone recovery in interpreting PSA kinetics.
Tamim Niazi, MDCM, reviews DASL-HiCaP findings showing improved metastasis-free survival with darolutamide added to ADT and radiation therapy.
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
2
Survey: Service members and veterans with NMIBC report barriers to treatment access
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
Q&A: Ronald Anglade, MD, on genetic testing in male infertility
5